Results 41 to 50 of about 89 (70)

Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment

Pediatric Pulmonology, 2020
Linnea Chika Kristensen Ejiofor, Inger Hee Mabuza Mathiesen, Søren Jensen-Fangel   +2 more
exaly  

Ivacaftor/ivacaftor/lumacaftor

Reactions Weekly, 2022
openaire   +1 more source

Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR

American Journal of Respiratory and Critical Care Medicine, 2017
CARLOS Milla, Felix Ratjen, Gautham Marigowda   +2 more
exaly  

Lumacaftor (VX-809)

Drugs of the Future, 2012
null McPhail, G., null Clancy, J.P.
openaire   +1 more source

Brivaracetam, lumacaftor/ivacaftor, and deoxycholic acid

Journal of the American Pharmacists Association, 2016
Daniel A, Hussar, Jerry Rachel, George
openaire   +2 more sources

Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis

Journal of Cystic Fibrosis, 2019
Daniela Savi, Stefano Schiavetto, Nicholas J Simmonds   +2 more
exaly  

Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa

American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018
Roxanna Barnaby, Katja Koeppen, Amanda Nymon   +2 more
exaly  

Ivacaftor/lumacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2023
openaire   +1 more source

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease

Journal of Cystic Fibrosis, 2017
Dominique Hubert, Raphaël Chiron, Boubou Camara   +2 more
exaly  

Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor

Organic Process Research and Development, 2019
David L Hughes
exaly